1h Free Analyst Time
Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
According to the recently published report 'Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 17 molecules.
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.
The report 'Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020' outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 1, 1, 7 and 1 respectively. The report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Oncology, Ophthalmology, Respiratory, Gastrointestinal, Genetic Disorders, Immunology and Metabolic Disorders which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Congenital Ichthyosis, Fibrosis, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Head And Neck Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Retinopathy Of Prematurity, Spondyloarthritis (Spondyloarthropathy), Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
- The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects
- The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development
- Advent Therapeutics Inc
- Avecho Biotechnology Ltd
- Bausch Health Companies Inc
- Boehringer Ingelheim International GmbH
- Galderma SA
- Ipsen SA
- Lee's Pharmaceutical Holdings Ltd
- Orphanix GmbH
- Ortho Dermatologics Inc
- Promius Pharma LLC
- Sol-Gel Technologies Ltd
- Sveikatal Inc
- TherapyX Inc
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles
- (adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (adapalene + clindamycin hydrochloride) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (benzoyl peroxide + tretinoin) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (benzoyl peroxide + tretinoin) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (TPX-6001 + tretinoin) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- alitretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- bexarotene + CD-1530 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- palovarotene - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Antagonize ROR-Gamma for Autoimmune Disorders, Allergies and Spondylosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Agonize RARG for Fibrosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tazarotene - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tazarotene - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- trifarotene - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- vitamin A palmitate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- vitamin A palmitate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones
- Featured News & Press Releases
- Mar 27, 2020: Ipsen to restart dosing of palovarotene in FOP studies
- Jan 27, 2020: Ipsen temporarily stops palovarotene dosing in FOP trials
- Jan 21, 2020: Sol-Gel announces presentation on Twyneo at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
- Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Journal of Drugs in Dermatology (JDD)
- Jan 08, 2020: Certara partners with Galderma in advancing modeling and simulation technology to attain FDA approval of AKLIEF topical Acne cream
- Jan 08, 2020: Sol-Gel hosts investor call to discuss positive results from Twyneo phase 3 program in Acne Vulgaris
- Dec 30, 2019: Sol-Gel announces positive top-line phase 3 trial results of Twyneo for the treatment of acne vulgaris
- Dec 20, 2019: Galderma receives a positive outcome through the European Decentralised Procedure for AKLIEF (trifarotene 50 mcg/g cream), the first new retinoid molecule for acne in the European Union in 25 years
- Dec 19, 2019: FDA approves Ortho Dermatologics' ARAZLO (Tazarotene) lotion, 0.045%, for acne vulgaris
- Dec 09, 2019: Ipsen initiates partial clinical hold for palovarotene IND120181 and IND135403 studies
- Nov 28, 2019: First new retinoid molecule approved in over 20 years
- Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on tazarotene at The Fall Clinical Dermatology Conference
- Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on acne drug tretinoin at The Fall Clinical Dermatology Conference
- Oct 04, 2019: Galderma receives FDA approval for AKLIEF (trifarotene) cream, 0.005%, the first new retinoid molecule for the treatment of Acne in over 20 years
- Aug 07, 2019: Ortho Dermatologics announces U.S. FDA filing acceptance for IDP-123 treatment for Acne Vulgaris in lotion form
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Information
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indication, H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by Advent Therapeutics Inc, H1 2020
- Pipeline by Avecho Biotechnology Ltd, H1 2020
- Pipeline by Bausch Health Companies Inc, H1 2020
- Pipeline by Boehringer Ingelheim International GmbH, H1 2020
- Pipeline by Galderma SA, H1 2020
- Pipeline by Ipsen SA, H1 2020
- Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020
- Pipeline by Orphanix GmbH, H1 2020
- Pipeline by Ortho Dermatologics Inc, H1 2020
- Pipeline by Promius Pharma LLC, H1 2020
- Pipeline by Sol-Gel Technologies Ltd, H1 2020
- Pipeline by Sveikatal Inc, H1 2020
- Pipeline by TherapyX Inc, H1 2020
- Dormant Products, H1 2020
- Dormant Products, H1 2020 (Contd..1), H1 2020
- Discontinued Products, H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Mechanism of Actions, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Routes of Administration, H1 2020
- Number of Products by Stage and Routes of Administration, H1 2020
- Number of Products by Molecule Types, H1 2020
- Number of Products by Stage and Molecule Types, H1 2020
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advent Therapeutics Inc
- Avecho Biotechnology Ltd
- Bausch Health Companies Inc
- Boehringer Ingelheim International GmbH
- Galderma SA
- Ipsen SA
- Lee's Pharmaceutical Holdings Ltd
- Orphanix GmbH
- Ortho Dermatologics Inc
- Promius Pharma LLC
- Sol-Gel Technologies Ltd
- Sveikatal Inc
- TherapyX Inc
